X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds from the financing will be used to support the launch of Zimed PF (bimatoprost) for the reduction of elevated intraocular pressure (IOP) in patients with open - angled glaucoma or ocular hypertension.
Lead Product(s): Bimatoprost
Therapeutic Area: Ophthalmology Product Name: Zimed PF
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Mr. Doug Janzen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing April 05, 2023
Details:
Zimed PF (bimatoprost) a preservative-free, ophthalmic solution, is a prostaglandin approved for the reduction of elevated IOP in patients with open angle glaucoma or ocular hypertension by selectively mimicking the effects of naturally occurring substances, prostamides.
Lead Product(s): Bimatoprost
Therapeutic Area: Ophthalmology Product Name: Zimed PF
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sandoz B2B
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2022
Details:
Under the agreement, Sandoz gained access to both Vistitan and Tacrolimus IR. Vistitan (bimatoprost) is a prostaglandin for IOP lowering in patients with open-angle glaucoma or ocular hypertension.
Lead Product(s): Bimatoprost
Therapeutic Area: Ophthalmology Product Name: Vistitan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sandoz B2B
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 29, 2022
Details:
Under the agreement, Sandoz gained access to both Vistitan and Tacrolimus IR. Vistitan (bimatoprost) is a prostaglandin for IOP lowering in patients with open-angle glaucoma or ocular hypertension.
Lead Product(s): Bimatoprost
Therapeutic Area: Ophthalmology Product Name: Vistitan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sandoz B2B
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 11, 2022
Details:
Zimed PF (bimatoprost) a preservative-free, ophthalmic solution, is a prostaglandin approved for the reduction of elevated IOP in patients with open angle glaucoma or ocular hypertension by selectively mimicking the effects of naturally occurring substances, prostamides.
Lead Product(s): Bimatoprost
Therapeutic Area: Ophthalmology Product Name: Zimed PF
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2022
Details:
Aequus has agreed to an extension of terms for its promotional service agreement with Sandoz Canada Inc. on tacrolimus immediate-release Tacrolimus IR to December 31st, 2021.
Lead Product(s): Tacrolimus
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sandoz B2B
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 16, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
